

Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: Wendy London, Ph.D.

Committee: Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC)

Meeting Date: October 31, 2023

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the agenda item: Sickle Cell disease, I may be considered for participation in the advisory committee meeting described above.

Type of Interest	Nature	Magnitude
I. Other Imputed Interests		
Employment at Boston Children's Hospital	Clinical Trial	\$ 0 - 5000

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

<u>/s/</u>

Signature

October 16, 2023 Date

U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov